EUVIMEDEUVIMED entdecken
Multizentrische Studie

Residual Pulmonary Hypertension and Clinical Outcomes in Acute Decompensated Heart Failure Patients Stratified By Left Ventricular Ejection Fraction

Toshikazu D Tanaka iD, Yasuyuki Shiraishi, Ryeonshi Kang, Takashi Kohno, Satoshi Shoji, Toraaki Okuyama, Yuhei Oi, Ayumi Goda, Ryo Nakamaru, Yuji Nagatomo, Mitsunobu Kitamura, Munehisa Sakamoto und 6 weitere

European Journal of Heart Failure · 2025

DOI: 10.1002/ejhf.3755 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Heart Failure, 2025. Verfasst von Toshikazu D Tanaka und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Heart Failure, Stroke Volume, Hypertension, Pulmonary, Ventricular Function, Left. Die Arbeit nennt 40 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science, Health Labour Sciences Research, Sakakibara Clinical.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

The precise outcomes for patients with residual pulmonary hypertension (PH) following the optimized treatment of acute decompensated heart failure (ADHF) remain poorly understood. This study aimed to investigate the prognostic association of PH, categorized according to left ventricular ejection fraction (LVEF), in hospitalized ADHF patients. Methods and results The WET-HF registry is a multicentre, prospective cohort ADHF registry. Patients were classified into four groups according to tricuspid regurgitation velocity (TRV) and LVEF. PH was defined as peak TRV >2.8 m/s. The primary endpoint was a composite of all-cause mortality and heart failure (HF) rehospitalization at 2 years. In total, 1702 patients had nonPH-HF with LVEF <50% (n = 689 [40.5%]), PH-HF with LVEF <50% (n = 291 [17.1%]), nonPH-HF with LVEF ≥50% (n = 453 [26.6%]), and PH-HF with LVEF ≥50% (n = 269 [15.8%]). A significant difference in the composite endpoint was observed between patients with and without PH (42.3% vs. 30.4%, p < 0.001), with no significant interaction between PH and LVEF. Notably, in the nonPH-HF group, there were significant differences in clinical outcomes between patients with more than 30% B-type natriuretic peptide (BNP) improvement and those with less (composite endpoint 27.5% vs. 41.8%, p < 0.001; all-cause mortality 9.4% vs. 24.6%, p < 0.001; HF rehospitalization 20.2% vs. 32.8%, p = 0.001). However, no such difference was evident in the PH-HF group.

Conclusions

The prognostic importance of residual PH was comparable across both HF with reduced and preserved ejection fraction patients. While the prognostic significance of BNP improvement on clinical outcomes was attenuated in the presence of residual PH, utilizing residual PH for risk stratification effectively identified patients at increased risk of mortality and rehospitalization following ADHF, irrespective of their LVEF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureStroke VolumeHypertension, PulmonaryVentricular Function, LeftHumansMaleFemaleAgedRegistriesProspective StudiesPrognosisAcute DiseasePatient ReadmissionMiddle AgedFollow-Up Studies

Stichwörter der Autor:innen

Acute decompensated heart failureBrain natriuretic peptideOutcomesPulmonary hypertension

Autor:innen und Institutionen

  • Division of Cardiology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
  • Department of Cardiology, Keio University School of Medicine, Tokyo, Japan.
  • Department of Cardiovascular Medicine, Kyorin University Faculty of Medicine, Tokyo, Japan.
  • Duke Clinical Research Institute, Durham, NC, USA.
  • Department of Cardiology, National Defense Medical College, Saitama, Japan.
  • Department of Cardiology, Sakakibara Heart Institute, Tokyo, Japan.

ORCID-Profile: Toshikazu D Tanaka

Förderung

  • Japan Society for the Promotion of Science
  • Health Labour Sciences Research
  • Sakakibara Clinical
  • Japan Agency for Medical Research and Development
  • Clinical Research from the Japanese Circulation Society

Zitieren

APA

Tanaka, T. D., Shiraishi, Y., Kang, R., Kohno, T., Shoji, S., Okuyama, T., Oi, Y., Goda, A., Nakamaru, R., Nagatomo, Y., Kitamura, M., Sakamoto, M., Nomoto, M., Mizuno, A., Nagoshi, T., Kohsaka, S., Yoshikawa, T., & West Tokyo Heart Failure Registry Investigators (2025). Residual Pulmonary Hypertension and Clinical Outcomes in Acute Decompensated Heart Failure Patients Stratified By Left Ventricular Ejection Fraction. European Journal of Heart Failure. https://doi.org/10.1002/ejhf.3755

Vancouver

Tanaka TD, Shiraishi Y, Kang R, Kohno T, Shoji S, Okuyama T, et al. Residual Pulmonary Hypertension and Clinical Outcomes in Acute Decompensated Heart Failure Patients Stratified By Left Ventricular Ejection Fraction. European Journal of Heart Failure. 2025. doi:10.1002/ejhf.3755

BibTeX
@article{Tanaka2025,
  author = {Tanaka, Toshikazu D and Shiraishi, Yasuyuki and Kang, Ryeonshi and Kohno, Takashi and Shoji, Satoshi and Okuyama, Toraaki and Oi, Yuhei and Goda, Ayumi and Nakamaru, Ryo and Nagatomo, Yuji and Kitamura, Mitsunobu and Sakamoto, Munehisa and Nomoto, Michiru and Mizuno, Atsushi and Nagoshi, Tomohisa and Kohsaka, Shun and Yoshikawa, Tsutomu and West Tokyo Heart Failure Registry Investigators, West Tokyo Heart Failure Registry Investigators},
  title = {Residual Pulmonary Hypertension and Clinical Outcomes in Acute Decompensated Heart Failure Patients Stratified By Left Ventricular Ejection Fraction},
  journal = {European Journal of Heart Failure},
  year = {2025},
  doi = {10.1002/ejhf.3755}
}
Kostenlos starten →